Sleep Disorders

Nov 15, 2012 Issue
Updated Guidelines from AASM for the Treatment of Central Sleep Apnea Syndromes [Practice Guidelines]

The updated guidelines on central sleep apnea from the American Academy of Sleep Medicine (AASM) includes levels of recommendations (standard or option) based on the overall quality of evidence (high, moderate, low, or very low). Central sleep apnea syndromes are characterized by sleep-disordered br...

Feb 1, 2012 Issue
Respiratory Indications for Polysomnography in Children [Practice Guidelines]

Although assessment of sleep disorders in children relies on the history and physical examination, polysomnography (PSG) is sometimes used to aid in the diagnosis. The American Academy of Sleep Medicine has provided recommendations regarding the use of the test in children. This guideline focuses on...

Nov 1, 2011 Issue
Antidepressants for the Treatment of Insomnia in Patients with Depression [FPIN's Clinical Inquiries]

There is no single antidepressant or class of antidepressants that is most effective for the treatment of insomnia in patients with depression. The use of antidepressant medications can have a positive impact on sleep physiology, but does not seem to improve subjective ratings of sleep quality.

Aug 15, 2011 Issue
Doxepin (Silenor) for Insomnia [STEPS]

In older patients with primary insomnia, Silenor can increase duration of sleep without next-day effects. However, it does not significantly decrease the time to sleep onset, and it is less effective in younger adults.

May 1, 2011 Issue
Clinical Indicators of Obstructive Sleep Apnea [FPIN's Clinical Inquiries]

Clinical indicators (e.g., sex, snoring severity, history of apnea, age, menopausal status, waist-to-hip ratio, body habitus) can predict OSA as diagnosed using overnight polysomnography or sleep study.

Jan 15, 2010 Issue
Sleep Apnea [Clinical Evidence Handbook]

What are the effects of treatment for severe and nonsevere OSAHS?

Mar 1, 2009 Issue
Excessive Daytime Sleepiness [Article]

Excessive daytime sleepiness is one of the most common sleep-related patient symptoms, and it affects an estimated 20 percent of the population. Persons with excessive daytime sleepiness are at risk of motor vehicle and work-related incidents, and have poorer health than comparable adults. The most ...

Jan 15, 2009 Issue
Nonpharmacologic Management of Chronic Insomnia [Article]

Chronic insomnia is highly prevalent in our society, with an incidence of 10 to 30 percent. It is a major cost to society in terms of health care expenditure and reduced productivity. Nonpharmacologic interventions have been studied and shown to produce reliable and sustained improvements in sleep p...

Aug 15, 2007 Issue
Treatment Options for Insomnia [Article]

The frequency of sleep disruption and the degree to which insomnia significantly affects daytime function determine the need for evaluation and treatment. Physicians may initiate treatment of insomnia at an initial visit; for patients with a clear acute stressor such as grief, no further evaluation ...

Apr 15, 2006 Issue
Ramelteon (Rozerem) for Insomnia [STEPS]

Ramelteon is safe and effective for decreasing the time to persistent sleep in patients with chronic insomnia. It does not have the potential for abuse or dependence that sedative hypnotics have and is not a controlled substance.

Pages: Previous 1 2 3 4 5 6 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now